Perseus-Soros Biopharmaceutical Fund, LP
Aisling Capital · adviser of record: Aisling Capital LLC · 2012 vintage
Perseus-Soros Biopharmaceutical Fund, LP is a 2012 venture fund managed by Aisling Capital. It reported $30mm in gross assets at year-end 2014, against a peak of $68mm in 2012.
- Latest value held
- $30mm year-end 2014
- Peak
- $68mm year-end 2012
- Fund size
- Not on file
Value held by year-end
Gross asset value reported on Form ADV at each year-end. Open in the Fund Tracker
| Year-end | Gross assets | ÷ size | Change |
|---|---|---|---|
| 2014 | $30mm | – | -54% |
| 2013 | $65.1mm | – | -4% |
| 2012 | $68mm | – | – |
What public pensions report
| Investor | As of | Commitment | Cash back (DPI) | Total (TVPI) | Still held |
|---|---|---|---|---|---|
| New York Common | 2024-03-31 | $35mm | 1.42x | 1.42x | 0.00x |
| PA PSERS | 2023-09-30 | $107mm | 1.64x | 1.64x | 0.01x |
| University of California | 2020-06-30 | $10mm | 1.63x | 1.63x | 0.00x |
Latest report from each pension, as multiples of paid-in capital. Where a pension reports only the value it holds, that value is shown in dollars under Still held. Linked dates go to the pension’s report.
Other funds from Aisling Capital
About these numbers
Gross asset value is what the manager reports holding in the fund at each fiscal year-end, on SEC Form ADV, Schedule D. It includes the GP’s own commitment and is before carried interest, so it is not the LPs’ net return, and it does not show cash already distributed. A fall in value can mean distributions, markdowns or both. Fund size is the amount sold reported on Form D, which for some funds reflects only a first close. Private fund ID 805-5703280361. Data updated October 13, 2026.
Is this your fund?
Spot an error and email a correction. Facing DPI pressure? See how distribution financing works.